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1. Introduction
Bacterial meningitis (BM) is a serious cause of morbidity and
mortality in children worldwide.1 BM is more common in resource-
poor countries than in industrialized countries.2 Excluding cases
arising from epidemics, approximately one million cases of BM occur
every year, with approximately 170 000 of these being fatal.3 As a
number of new vaccines to prevent meningitis are either available or
in development, it is important to determine the etiology and
burden of meningitis to allow governments to make evidence-based
decisions about the introduction of these new vaccines. For a variety
of reasons, including disparities in drawing appropriate specimens
and suboptimal laboratory techniques, many low-resource coun-
tries have low yields of bacterial isolates making it difﬁcult to
quantify the disease burden due to speciﬁc organisms.
Childhood meningitis is caused by a number of viruses, bacteria,
and other microorganisms. The predominant causes of BM in
children older than 2 months of age are Streptococcus pneumoniae,
Neisseria meningitidis, and Haemophilus inﬂuenzae type b (Hib).4
Since the introduction of Hib vaccine, the incidence of Hib
meningitis has declined.4 S. pneumoniae is now the predominant
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S U M M A R Y
Objectives: To describe the etiology, epidemiology, neurological sequelae, and quality of life of children
aged 1 month to less than 5 years admitted with meningitis to the Colonial War Memorial Hospital
(CWMH), Suva, Fiji.
Methods: Over a 3-year period, all eligible children with suspected meningitis admitted to CWMH had
blood drawn for culture. Of these children, those for whom is was possible were tested for a four-fold rise
in antibody titers to Haemophilus inﬂuenzae type b (Hib) and pneumococcal surface adhesin A (PsaA).
Cerebrospinal ﬂuid (CSF) was taken for bacteriological culture and antigen testing. CSF was also tested by
PCR for Streptococcus species, Neisseria meningitidis, Hib, Mycobacterium tuberculosis, and enterovirus.
Pneumococcal isolates were serotyped using multiplex-PCR reverse-line blot hybridization. Following
discharge, cases underwent a neurological assessment, audiometry, and quality of life assessment
(Pediatric Quality of Life Inventory (PedsQL) tool).
Results: There were 70 meningitis cases. Meningitis was more common in indigenous Fijian than Indo-
Fijian children. Enterovirus was the most common etiological agent and appeared to be outbreak-
associated. Streptococcus pneumoniae was the most common bacterial cause of meningitis with an
annual incidence of 9.9 per 100 000 under 5 years old (95% conﬁdence interval 4.9–17.7) and a case
fatality rate of 36%. With the exception of deafness, neurological sequelae were more frequent in cases of
bacterial meningitis than in viral meningitis (18.5% vs. 0%, p = 0.04). Quality of life at follow-up was
signiﬁcantly lower in patients with bacterial meningitis than in those with viral meningitis (p = 0.003) or
meningitis of unknown etiology (p = 0.004).
Conclusions: During the study period an outbreak of enterovirus occurred making it the most common
etiological agent identiﬁed. However in the absence of this outbreak, S. pneumoniae was the most
common cause of childhood meningitis in Fiji. Bacterial meningitis is associated with serious sequelae
and a reduced quality of life.
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cause of non-epidemic BM; it was estimated to cause 103 000 cases
globally in the year 2000.5 The case fatality rate (CFR) for children
with BM varies by age of onset and etiology, but typically ranges
from 3% to 19% in industrialized settings.6 Higher CFR (37–60%)
have been reported in resource-poor countries, which may partly
be due to delayed access to health care.6 Neurological sequelae
following BM are common and occur more frequently in resource-
poor countries (up to 65%)7,8 compared with industrialized
countries (up to 25%). Rates of sequelae differ by etiology.7
For viral meningitis (otherwise known as aseptic meningitis),
enteroviruses are the most common cause.9 Certain enteroviruses
(coxsackie B5, echovirus 6, 9 and 30) are more likely to cause
meningitis outbreaks, while others (coxsackie A9, B3 and B4) are
mostly endemic.10
In Fiji, the Ministry of Health is currently contemplating the
introduction of a pneumococcal conjugate vaccine (PCV). In order
to make an evidence-based decision on the need for this vaccine,
the burden of disease needs to be established. The aim of this
prospective study was to describe the etiology, incidence, CFR,
neurological sequelae, and quality of life of children aged 1 month
to less than 5 years admitted with meningitis to the Colonial War
Memorial Hospital (CWMH) in Suva, Fiji.
2. Methods
2.1. Background to the study site
Fiji is located in the South Paciﬁc and consists of over 300
islands. The two main islands are Viti Levu and Vanua Levu, the
former being the largest. The total population of Fiji is 837 271
(2007 census). The total population aged under 5 years in the
catchment area is 33 979, with approximately 71% of these being
indigenous Fijian and 22% Indo-Fijian (Indian ethnicity) (2007
census). Health care is provided free of charge. Access to health
care is good as transport is generally affordable, most roads are
well developed, and health centers and nursing stations are widely
distributed in the rural areas. The infant mortality rate is 15.2/1000
live births,11 and it is uncommon for children to die at home before
receiving health care. The bacille Calmette–Gue´rin (BCG) vaccine is
given to all infants at birth, and a national three-dose infant Hib
vaccination schedule was introduced in Fiji in 1995, achieving high
coverage in recent years. PCV is not in routine use.
The health services in Fiji are divided into four medical
divisions. The population of children aged under 5 years in the
Central Medical Division is 33 979 (2007 census). All suspected
meningitis cases within the catchment population of the Central
Medical Division are referred and admitted to CWMH. CWMH is
the only hospital in the Central Medical Division that provides
pediatric intensive care services and is also the only hospital with
microbiology laboratory facilities. There are no private inpatient
services available in the catchment area.
2.2. Study design
This was a prospective study including children aged 1 month
to less than 5 years with suspected meningitis residing within the
Central Medical Division during the period October 1, 2004 to
September 30, 2007. All children admitted to CWMH with
suspected meningitis had a blood culture drawn and lumbar
puncture taken (unless contraindicated), and were commenced on
dexamethasone and intravenous ceftriaxone. In addition, infants
aged 1–2 months were commenced on intravenous ampicillin.
Antimicrobials were continued for 10 days and dexamethasone for
4 days. Infants less than 2 months of age were treated with
antimicrobials for 21 days. Antimicrobials were rationalized
according to the antimicrobial sensitivity pattern.
Cerebrospinal ﬂuid (CSF) was transported immediately to the
CWMH microbiology laboratory for microscopy, cell count,
biochemical analysis, and culture for bacteria. CSF was also tested
for pneumococcal antigen by immunochromatography (Binax-
NOW1 S. pneumoniae, Inverness Medical, Cranﬁeld, UK) and latex
antigen for S. pneumoniae, Hib, and N. meningitidis (Wellcogen1
bacterial antigen kit rapid latex agglutination test). Any remaining
CSF was stored at 70 8C. Blood was cultured using the BacT/
ALERT1 system (bioMe´rieux, Durham, NC, USA). Blood was
redrawn 7–10 days later, with serum separated by centrifugation
and stored at 70 8C until tested. Serum and CSF were transported
on dry ice to overseas laboratories for further testing. All
pneumococcal isolates were sent to the Pneumococcal Reference
Laboratory, Centre for Infectious Diseases and Microbiology,
Institute for Clinical Pathology and Medical Research, Westmead,
New South Wales, Australia, where they were serotyped using a
multiplex-PCR reverse-line hybridization assay.12,13
A meningitis case was deﬁned as having a CSF white blood cell
count (WBC) of >10  106/l or clinical features of meningitis as
determined by a pediatrician. A BM case included those with:
bacteria isolated from CSF; a positive CSF for bacterial antigen; a
purulent but sterile CSF with a positive blood culture; autopsy
conﬁrmation; a subdural effusion on computed tomography (CT)
scan; CSF WBC 100  106/l; CSF WBC 10–99  106/l with glucose
<4 mmol/l and protein >100 mg/dl; causative organisms identi-
ﬁed through CSF PCR for Streptococcus spp, N. meningitidis, Hib, or
Mycobacterium tuberculosis; a four-fold rise in anti Hib-ELISA or
pneumococcal surface adhesin A (PsaA) titer14 on paired sera
(performed at the Royal Children’s Hospital, Melbourne, and the
Vaccine Trials group of the Telethon Institute, Princess Margaret
Hospital, University of Western Australia, respectively).
Cases of viral meningitis included those with negative
laboratory results as previously listed, and a positive CSF PCR
for enterovirus.15 A case of meningitis of unknown etiology
included those negative for all criteria listed previously, or with
clinical meningitis as conﬁrmed by a pediatrician, in whom a
lumbar puncture was contraindicated.
Children with nosocomial infections and those admitted for
bacterial meningitis who lived outside the deﬁned catchment area
were excluded from the study.
Clinical management, outcomes, and complications were
documented during the hospital admission. Short- and long-term
morbidities were assessed at approximately 6–8 weeks and 6
months following discharge. The children were reviewed to assess
neurological sequelae by a neurological examination undertaken
by a trained doctor (VB). Tests for vision included the assessment of
pupillary light reﬂex, presence of nystagmus, extraocular move-
ments, and visual ﬁeld testing where possible. At review, all
parents were asked to complete a validated16 standardized quality
of life questionnaire (Pediatric Quality of Life Inventory tool
(PedsQL); Mapi Research Institute, Lyon, France) to rate their
child’s functioning. The questionnaire assessed functioning in four
broad areas: physical, emotional, social, and, where old enough,
school performance.17,18 An experienced pediatric audiologist
performed audiometry including pure tone audiometry, behavioral
observation audiometry, auditory brainstem response testing,
visual reinforcement audiometry, or impedance audiometry on all
available children. Mild, moderate, severe, and profound hearing
loss were deﬁned as on average the most quiet sounds heard with
the better ear at 26–35 dB, 36–60 dB, 61–90 dB, and 90 dB,
respectively.
2.3. RNA extraction from CSF
All procedures were carried out in a class II biohazard cabinet to
minimize the risk of contamination. Bacterial RNA was extracted
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from CSF using the FastRNA1 Pro Blue Kit (Qbiogene), and viral RNA
was extracted using the High Pure Viral Nucleic Acid Kit (Roche), in
accordance with the manufacturers’ instructions. Brieﬂy, CSF was
centrifuged for 20 min at 4 8C and 16 100  g. The volume of each
sample was recorded and the CSF was transferred to a new 1.5-ml
Eppendorf tube for RNA extraction, whilst the pellet was processed
using the bacterial RNA kit. Finally, the RNA was resuspended in
either 50 ml of diethylpyrocarbonate (DEPC)-water (bacteria) or
50 ml of elution buffer (virus). RNA was also extracted from a pool of
CSF taken from control patients and proved to be bacteria- and virus-
negative by reverse transcriptase (RT)-PCR.
2.4. Detection of bacterial and enteroviral RNA
Bacterial and enteroviral RNA was detected using the Superscript
III One Step RT-PCR System with Platinum Taq DNA Polymerase
(Invitrogen). Each 50-ml reaction contained 10 mM of each primer
(Table 1 3,19–21) and 5 ml of RNA template. Cycle conditions were as
per the manufacturer’s instructions with slight modiﬁcations. For
bacterial detection, cDNA was ampliﬁed at 55 8C for 15 min,
followed by heat denaturation at 94 8C for 2 min, 30 cycles with
heat denaturation at 94 8C for 15 s, 55 8C annealing for 30 s, and
extension at 68 8C for 40 s. Enterovirus RNA was detected by
amplifying cDNA at 55 8C for 30 min, followed by heat denaturation
at 94 8C for 2 min, 40 cycles of heat denaturation at 94 8C for 15 s,
55 8C annealing for 30 s, and extension at 68 8C for 15 s. First round
enteroviral products were diluted 1:500 in PCR-grade water; 2 ml of
this sample served as template in the second round PCR, which was
performed in a 26-ml reaction mixture containing 2 mM of MgCl2,
each of the deoxyribonucleotides at 0.2 mM, each primer at 0.4 mM,
and 0.025 U of Taq DNA polymerase. The following cycles were
applied: initial heat denaturation at 94 8C for 2 min, 35 cycles with
heat denaturation at 94 8C for 20 s, 55 8C annealing for 20 s, and
extension at 72 8C for 30 s. PCR products were visualized by 2.0%
agarose gel electrophoresis with 1X Tris–acetate–EDTA (TAE) buffer
containing 1X SYBRTM Safe (Invitrogen).
2.5. Speciﬁcity and sensitivity of the RT-PCR assays
RNA extracted from the four control bacteria were used as
positive controls to test the speciﬁcity of the multiplex RT-PCR.
Negative controls consisted of Escherichia coli RNA and RNA
extracted from a pool of normal CSF samples. Only the bacteria of
interest produced an amplicon of the relevant size.20,22 RNA
extracted from enterovirus 71 (EV71) was used as positive
enterovirus control. RNA extracted from a pool of patient CSF
was used as a negative control.
To determine the lower limit of detection, 10-fold serial
dilutions of S. pneumoniae ranging from 7.5  104 to 103 CFU/ml
were prepared. For M. tuberculosis, 100 ml of spiked sputum was
used neat and serially diluted. The dilutions of bacteria were used
to spike 500 ml of the control CSF. Similarly, 100 ml of EV71 was
serially diluted 10-fold (106 to 101 TCID50 (median tissue culture
infective dose)) and used to spike 100 ml of control CSF. All spiked
controls were frozen at 70 8C for approximately 4 weeks to mimic
the Fijian CSF storage conditions. The sensitivity of detection of S.
pneumoniae from frozen CSF was 750 genomes per CSF sample, and
50 ml of the M. tuberculosis suspension, whilst the limit of RNA
detection was 1.3 pg. The sensitivity for viral detection was 10
TCID50 of EV71 extracted from frozen CSF.
2.6. Sequencing and bioinformatics
PCR products were excised from agarose and puriﬁed using the
QIAquick Gel Extraction Kit (Qiagen) in accordance with the
manufacturer’s instructions. The sequencing reactions were
performed with the Big Dye Terminator Cycle Sequencing Kit
v1.3 (Applied Biosystems) and cycle reactions were then puriﬁed
using the DyeEx 2.0 Spin Kit (Qiagen) in accordance with the
manufacturers’ instructions. The resulting sequences were com-
pared to sequences stored in GenBank using the local alignment
search tool (BLAST; http://www.ncbi.nlm.nih.gov/BLAST/).
2.7. Statistical analysis
Data were exported to Stata version 9.0 (Stata Corp., College
Station, TX, USA) for analysis. Chi-square or Fisher’s exact tests
were used to test for statistically signiﬁcant differences between
categorical variables at the p < 0.05 level. For the PedsQL
questionnaire, a total score was calculated for each case using an
internationally validated standard PedsQL scoring system.17,18
As a reference point, a total score of 90 was the mean score
found in healthy children in developed countries.17,18 A mean
total score was calculated for each of the three categories of
meningitis. In addition, mean scores were calculated for each
PedsQL subgroup: the mean psychosocial health summary (the
mean of the sum of the items in this category divided by the
number of items answered in the emotional, social, and school
functioning scales) and the mean physical health summary (the
physical functioning scale score). The mean scores were
compared using an unpaired t-test for each meningitis category.
Incidence rates were calculated based on the number of cases for
each organism with the catchment population taken from the
2007 census.
Table 1
Details of oligonucleotide primers used in this study
Primer name Sequence (50–30) Target organism and gene Position in gene
sequence
Amplicon
size (bp)
Reference
TB1 CGAACGGAAAGGTCTCTTCGGAGA Mycobacterium tuberculosis 16S rRNA 65–88 138 19
TB2 ACCACAAGACATGCATCCCGTGGT M. tuberculosis 16S rRNA 202–179
STREP GTACAACGAGTCGCAAGC Streptococcus spp 16S rRNA 265a 20
HI CCTAAGAAGAGCTCAGAG Haemophilus inﬂuenzae 16S rRNA 909–926 513a 20
NM TGTTGGGCAACCTGATTG Neisseria meningitidis 16S rRNA 823–840 679a 20
1492R GGTTACCTTGTTACGACTT 16S rRNA universal for domain Bacteria 1510–1492b 3
EV1-Rc GCCGCATTCAGGGGCCG Enterovirus (family Picornaviridae) gene
polyprotein, VP4 and VP2 region
468–451d 303 Winnie Sime
UG52 CAAGCACTTCTGTTTCCCCGG 165–185d - 21
UC53c TTGTCACCATAASCAGCCA 600–581d 435 21
a When paired with universal primer 1492R.
b Location in the Escherichia coli 16S rRNA gene.
c When paired with sense primer UG52.
d Location in enterovirus 71 strain TW/2086/98.
e Enteric Virus Group, Murdoch Children’s Research Institute.
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2.8. Ethics approval
Ethics approval for this study was granted by the Human
Research Ethics Review Committee, the University of Melbourne,
Australia, and the Fiji National Research Ethics Review Committee.
3. Results
During the 3-year study period, 112 cases of suspected
meningitis were identiﬁed, with 76 ﬁtting the inclusion criteria.
Six refused consent resulting in 70 cases of meningitis that were
available for analysis. Table 2 shows the demographic character-
istics of the cases. Most patients with meningitis were indigenous
Fijians (89%), and were infants (70%). Although enterovirus was the
single most common cause of meningitis, BM was diagnosed in 46
(66%) of the patients overall.
Table 3 shows the clinical features of children with meningitis.
Data on clinical features on admission were collected for 35 of the
46 children with BM, as 11 children died on arrival at hospital.
These 11 children had meningitis conﬁrmed by autopsy. Children
with BM commonly presented with high fever, neck stiffness, and
signs of raised intracranial pressure. Children with viral meningitis
commonly presented with high fever and vomiting and less
frequently presented with features of raised intracranial pressure
compared with those with BM. High fever and neck stiffness were
common in cases of meningitis of unknown etiology.
During admission, seizures were signiﬁcantly more common in
BM cases compared with viral meningitis and cases of unknown
etiology (Table 3). There were no signiﬁcant differences in
sensorineural deafness between any of the three meningitis
groups. The frequency of other neurological sequelae was
signiﬁcantly higher in the BM group compared with the viral
meningitis group (18.5% vs. 0%, p = 0.04). The CFR for BM was 34%.
Of the survivors, the overall quality of life score (mean PedsQL
score) was signiﬁcantly lower in the cases with BM compared with
both those with viral meningitis (p = 0.003) and those with
meningitis of unknown etiology (p = 0.004) (Table 3). Also,
signiﬁcantly lower scores were found in BM cases compared with
viral meningitis cases and with cases of unknown etiology for the
two PedsQL subcategories: the mean psychosocial health score and
the mean physical health score.
Of the 59 survivors, 40 had CSF samples available for PCR
testing, and of these 14 (35%) were positive for a causative
organism that was otherwise undetected by routine laboratory
methods. Twelve CSF samples were positive for enterovirus only
(30%), representing 17.1% of all meningitis cases. Five (12.5%) CSF
samples were positive for S. pneumoniae and two (5%) were
positive for H. inﬂuenzae. No samples were positive for N.
meningitidis or M. tuberculosis. Forty of the 59 CSF samples were
tested using BinaxNOW S. pneumoniae with 10 positive results.
One additional pneumococcal case was identiﬁed by PCR and no
additional cases were identiﬁed by BinaxNOW S. pneumoniae
alone.
Figure 1 shows the etiology of BM cases. Of the 46 BM cases, 43%
had a speciﬁc etiologic agent identiﬁed. S. pneumoniae was the
most common bacterial cause of meningitis (n = 11), followed by N.
meningitidis (n = 3). The N. meningitidis cases were all identiﬁed by
routine laboratory tests as there was insufﬁcient CSF available to
perform PCR. There were two cases each of Hib and group B
Streptococcus. The two cases of Hib meningitis were blood culture-
conﬁrmed as well as CSF latex antigen-positive and had previously
received three doses of Hib vaccine at 6, 10, and 14 weeks
respectively, as per the immunization schedule of Fiji.
There were 14 paired sera available for testing. No additional
pneumococcal or Hib cases were identiﬁed by serology. Only one
case had a two-fold rise in PsaA titer.
The annual incidence of pneumococcal meningitis in those aged
under 5 years was 9.9 per 100 000 (95% conﬁdence interval (CI)
4.9–17.7). All of the children with pneumococcal meningitis were
Table 2
Demographic features of children with meningitis (n = 70)
Bacterial meningitis
(n = 46), n (%)
Viral meningitis
(n = 12), n (%)
Meningitis of unknown etiology
(n = 12), n (%)
Ethnicity
Indigenous Fijians 40 (87.0) 10 (83.3) 12 (100)
Indo-Fijian 3 (6.5) 2 (16.7) 0
Others 3 (6.5) 0 0
Gender
Male 23 (50) 8 (66.7) 7 (58.3)
Female 20 (43.5) 4 (33.3) 5 (41.7)
Unknown 3 (6.5) 0 0
Age
1 month 4 (8.7) 1 (8.3) 0
2–5 months 17 (37.0) 2 (16.7) 3 (25)
6–11 months 14 (30.4) 3 (25) 5 (41.7)
1 year 4 (8.7) 2 (16.7) 1 (8.3)
2–4 years 5 (10.9) 4 (33.3) 3 (25)
Unknown 2 (4.3) 0 0
Figure 1. Etiology of bacterial meningitis (n = 20).
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indigenous Fijian. The annual incidence for pneumococcal
meningitis in indigenous Fijians was 15.3 per 100 000 (95% CI
5.1–16.4) in those under 5 years old. The CFR for pneumococcal
meningitis was 36% (n = 4). Eight of the pneumococcal isolates
were serotyped and included both PCV serotypes (1, 3, 6B (2 cases),
and 14 (2 cases)) and non-PCV serotypes (8 and 10F). Two of the
eight serotyped cases died. Both were PCV serotypes. Three of the
children with pneumococcal meningitis had neurological sequelae.
The child with serotype 1 was hemiplegic; the child with serotype
3 had hypotonia of the lower limbs; and the child with serotype 8
had ongoing seizures.
4. Discussion
In this study, enterovirus was the most common cause of
childhood meningitis. Interestingly, all enterovirus-associated
cases occurred within a 5-month period, with most of the cases
(75%) occurring within 2 months of study commencement,
indicating an epidemic. Enteroviral meningitis epidemics have
been described in many other settings23 and are commonly due to
coxsackie B5 and echoviruses 6, 9, and 30.10 Importantly, these
enteroviral meningitis cases ﬁtted the purulent meningitis case
deﬁnition, which is used in many BM surveillance studies, and
therefore this may overly attribute the meningitis disease burden
to a bacterial rather than a viral etiology. However, the duration of
the enterovirus outbreak was very short (5 months out of 36
months of surveillance). Had this outbreak not occurred, S.
pneumoniae would have been the most common cause of
childhood meningitis. This is consistent with other countries
where Hib vaccine is routinely used resulting in very low rates of
Hib meningitis.24 Comparing disease burden rates between
geographical sites is difﬁcult due to many factors including
under-reporting, differences in reporting methods, antimicrobial
prescribing practices, and disparities in blood culture practice and
laboratory techniques. To address this, the World Health
Organization and the Pneumococcal vaccines Accelerated Devel-
opment and Introduction Plan (PneumoADIP) have standardized
case deﬁnitions and have supported a coordinated multisite
surveillance project of pneumococcal disease in Asia and Africa.25
The incidence of pneumococcal meningitis in our study is slightly
higher than that found in the UK26 and non-indigenous Australia
prior to PCV introduction,27 but lower than reported rates in the
Gambia28 and in the indigenous Australian population.29 In our
study the CFR for pneumococcal meningitis was higher (34%) than
that in Bangladesh8 and in the multisite surveillance studies in Asia
and Africa,25 but lower than that in Malawi.30 Of the seven
pneumococcal meningitis survivors, neurological sequelae were
evident in 14%, which is a lower rate than that in Bangladesh8 and
considerably lower than in a cohort study in Senegal.7 These
differences may be due to under-reporting from loss to follow-up
and differences in the neurological and developmental assess-
ments undertaken.
Pneumococcal meningitis occurred only in indigenous Fijian
children. Higher rates of pneumococcal nasopharyngeal carriage,31
hospitalization with X-ray conﬁrmed pneumonia,32 and invasive
pneumococcal disease (IPD) have been documented previously
amongst the indigenous pediatric population in Fiji.33 This may be
due to environmental factors or a genetic susceptibility. Ethnic
disparities in pneumococcal disease burden have been described
elsewhere.29,34
Table 3
Clinical presentation, complications, neurological sequelae, and quality of life scores of children with meningitis
Bacterial meningitis
(n = 35a), n (%)
Viral meningitis
(n = 12), n (%)
Meningitis of unknown
etiology (n = 12), n (%)
Clinical features
Temperature 38.0 8C 19 (54.3) 8 (66.7) 9 (75)
Glasgow coma score <15 17 (48.6) 0 2 (16.7)
Neck stiffness 21 (60) 3 (25)b 4 (33.3)c
Photophobia 1 (2.9) 1 (8.3) 0
Vomiting 13 (37.1) 10 (83.3) 3 (25)c,d
High pitched crying 2 (5.7) 0 0
Bulging fontanelle 17 (48.6) 1 (8.3)b 3 (25)c
Papilledema 0 0 0
Shock 4 (11.4) 0 0
Focal neurological signs 0 0 0
Seizures 19 (54.3) 2 (16.7)b 4 (33.3)c
SIADH 2 (5.7) 0 0
Pneumonia 3 (8.6) 0 0
Circulatory shock 3 (8.6) 0 0
Subdural effusion 7 (20) 0b 0c
Spasticity 4 (11.4) 0 1 (8.3)
Paresis 2 (5.7) 0 1 (8.3)
Sequelae at discharge 3/30e (10) 0 3 (25)
Sequelae at follow-up
Sensorineural deafnessf 1/16 (6.3) 2/8 (25) 2/9 (22.2)
Other neurological sequelae 5/27g (18.5) 0b 1 (8.3)
Mean PedsQL scoreh at follow-up 64.8 (95% CI 43.9–85.8) 93.4b (95% CI 82.2–104.5) 97.4c (95% CI 88.2–106.4)
Mean psychosocial health score 77.5 (95% CI 59.8–95.2) 93.2b (95% CI 83.7–102.7) 96.8c (95% CI 93.6–100.1)
Mean physical health score 73.2 (95% CI 52.2–94.2) 93b (95% CI 77.5–108.4) 98.3c (95% CI 96.4–100.3)
Case fatality rate 34% 0 0
BM, bacterial meningitis; SIADH, syndrome of inappropriate anti diuretic hormone; 95% CI, 95% conﬁdence interval.
a Clinical data were available for 35/46 children with BM; the 11 children without clinical presentation data available died prior to hospitalization.
b p < 0.05, comparing BM with viral meningitis.
c p < 0.05, comparing BM with meningitis of unknown etiology.
d p < 0.05, comparing viral meningitis with meningitis of unknown etiology.
e Data for sequelae at discharge were available for 30/35 children as ﬁve died whilst in hospital.
f 33/54 survivors were available for audiology, with 21 being lost to follow-up.
g 27/35 BM children had a follow-up neurological assessment; three were lost to follow-up and ﬁve died during hospital admission.
h 46/54 of the surviving children were evaluated by using the PedsQL; of the eight who were not evaluated, ﬁve could not be contacted and three were out of the age range
for testing.
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In this study, there were few pneumococcal isolates available
for serotyping. However the potential PCV coverage of IPD for those
under 5 years of age in Fiji has been reported previously.34
Potential coverage by PCV for IPD improved as the valency
increased (7-valent 53.3%, 10-valent 66.7%, 13-valent 83.3%).33
Hib meningitis was uncommon in our study, as Hib vaccine has
been part of the national immunization schedule in Fiji for over 10
years. The annual incidence was 1.8 per 100 000 children aged
under 5 years, which is similar to that in other countries that
routinely use Hib vaccine24 and is the rate expected due to vaccine
failures.25 Fiji has achieved this low rate despite a 6, 10, 14 week
primary series schedule without a booster. In contrast, the UK
introduced a Hib vaccine booster in 2006 following a rise in the
incidence of invasive Hib disease with a three-dose primary series
without a booster.24 Ongoing surveillance in Fiji will be required to
ensure that this low rate is sustained.
Meningococcal meningitis was uncommon in our study. This is
in contrast to the high rates documented in the Paciﬁc Islander
community living in New Zealand and necessitating the imple-
mentation of a novel vaccine.35 It is unclear why the rates of
meningococcal meningitis differ in different geographic areas
among ethnically similar populations, but this is likely to be due to
environmental factors such as overcrowding. In addition, there
were no cases of TB meningitis in this study.
Low rates of sensorineural deafness were observed at follow-
up, with no signiﬁcant difference found by type of meningitis. This
may be due to the small sample size and the fact that follow-up
was not complete for all study participants, as these rates are lower
than those reported from Mexico,36 Bangladesh,8 and the
Netherlands.37
Our study also showed that 10% of BM cases had documented
sequelae at the time of hospital discharge, and that 18.5% had
neurological sequelae 6 months later. In addition, the quality of life
in survivors was signiﬁcantly lower than that in children with viral
meningitis. A previous cohort study from Fiji showed that the
quality of life in children with BM was signiﬁcantly lower than that
in otherwise healthy controls.16 A meta-analysis in the UK found a
10-fold increase in the risk of severe or moderate disability at 5
years of age among children who had BM compared with controls
(relative risk = 10.3, 95% CI 6.7–16.0, p < 0.001), with sequelae
noted in 15.6% of the cases.26 A prospective cohort study in Senegal
found multiple impairments and reduced quality of life in
survivors of BM, which varied by etiology.7 A review of African
studies showed pneumococcal and Hib meningitis to cause
clinically evident sequelae in a quarter of survivors prior to
hospital discharge.38 These ﬁndings indicate that signiﬁcant
lifelong disabilities are common following BM. Moreover, it is
important that services are developed to improve the detection
and clinical care of children at risk of sequelae that may not be
evident at the time of hospital discharge or too subtle to detect at
an early age.8
In the current study, more than one third of children with BM
died during the episode, which is similar to ﬁndings from Africa5,38
and much higher than rates documented in the Apache Indians of
Alaska.39 The global CFR for S. pneumoniae meningitis is estimated
to be 59%, ranging from 29% in the Western Paciﬁc to 73% in Africa.5
The high CFR in this study may be due to delayed health seeking
behavior or delays in treatment and referral from the referral
center, or may reﬂect an under-reporting in other centers, as it is
unlikely that any deaths were missed during the study period. In
other studies, Malawian and Bangladeshi children with BM who
presented late for health care had poorer outcomes.30
Our reason for using 16S rRNA as the target for our PCR was that
the volume of CSF available for testing was extremely small and
also that we wanted to examine each sample for M. tuberculosis,
Hib, meningococcus, Streptococcus, and enterovirus. Speciﬁcally,
the rationale for our decision was that: (1) multiplex PCR allowed
us to test for a range of agents in a sample of limited volume, and
(2) targeting 16S rRNA took advantage of a very high copy number
target compared with genomic DNA (1 copy of a diagnostic marker
per cell) or rDNA (7–8 copies per cell). Because RNA degrades when
bacterial cells die, we conducted a preliminary study to compare
fresh and frozen (stored for a month) spiked specimens of sterile
CSF, and found that our sensitivity of detection fell by less than 1
log, demonstrating that the rRNA was still largely intact. This is
partly because rRNA persists far longer after cell death than
mRNA.40 Another advantage of our method is that it combined the
generation of cDNA and its subsequent ampliﬁcation in a single
tube, thus reducing the possibility of contamination from
excessive handling.
Our decision to target 16S rRNA was vindicated by the results of
the study, which showed the PCR to be 67% sensitive and 91%
speciﬁc (with positive and negative predictive values of 80% and
83%, respectively) compared with traditional diagnosis (positive
blood or CSF culture, antigen detection, or Gram stain). However,
only one additional bacterial cause of meningitis was identiﬁed
using PCR that was not otherwise detected by routine laboratory
tests. In 12 of the 70 cases the etiology could not be established.
These 12 cases had purulent CSF and the meningitis may have been
caused by other organisms that were not tested for. Another
contributing factor is that the tests used were not 100% sensitive or
speciﬁc.
BinaxNOW S. pneumoniae did not identify any additional cases
of pneumococcal meningitis that were not identiﬁed by routine
laboratory tests. Other studies have found BinaxNOW S. pneumo-
niae to be a useful additional test in identifying additional
pneumococcal cases in Asian, but not African, sites.41 Despite
these additional diagnostic tests adding little value in our setting,
these tests may well add value in other settings where the burden
of these diseases may be higher and there are more samples for
testing. On the other hand, analysis of CSF by PCR did enable the
identiﬁcation of enterovirus as an etiological agent that was
otherwise not detected by routine laboratory examination.
In summary, enteroviral meningitis was the most common
childhood meningitis in Fiji, but appears to be outbreak-associated.
In the absence of the outbreak, S. pneumoniae was the most
common cause of endemic meningitis. Overall, BM was associated
with serious sequelae and a lower quality of life in Fijian children.
Acknowledgements
The authors wish to thank the patients enrolled in the study and
their parents, Shirley Warren, Catherine Lowry, the pediatric and
microbiology staff of CWMH, the Fiji Pneumococcal Project staff,
Professor Lyn Gilbert, Shahin Oftadeh, and Catherine Satzke.
Funding was kindly provided by PneumoADIP.
Conﬂict of interest: Associate Professor Richmond has served on
advisory boards for Baxter and Wyeth vaccines. He has received
institutional funding for epidemiological research from Glaxo
Smith Kline (GSK) and Commonwealth Serum Laboratories
Limited. He has received travel support to present the data of
multicenter sponsored studies from Pﬁzer, Baxter, and GSK.
References
1. Dawson KG, Emerson KC, Burns JL. Fifteen years of experience with bacterial
meningitis. Pediatr Infect Dis J 1999;18:816–22.
2. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a
meta-analysis. Pediatr Infect Dis J 1993;12:389–94.
3. World Health Organization. New and Under-utilized Vaccines Implementation
(NUVI). Bacterial meningitis. Geneva: WHO; August 2010. Available at: http://
www.who.int/nuvi/meningitis/en/ (accessed October 13, 2010).
4. Popovic T, Ajello G, Facklam R. Laboratory methods for the diagnosis of
meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae and
V.L. Biaukula et al. / International Journal of Infectious Diseases 16 (2012) e289–e295e294
Haemophilus inﬂuenzae. World Health Organization Communicable Disease
Surveillance and Response. WHO/CDS/CSR/EDC/99/7/EN. Geneva: WHO;
1998. Available at: http://www.who.int/csr/resources/publications/meningitis/
WHO_CDS_CSR_EDC_99_7_EN/en/ (accessed July 23, 2008).
5. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Hib
and Pneumococcal Global Burden of Disease Study Team. Burden of disease
caused by Streptococcus pneumoniae in children younger than 5 years: global
estimates. Lancet 2009;374:893–902.
6. Saez-Llorens X, McCracken GH. Bacterial meningitis in children. Lancet 2003;21:
2139–48.
7. Edmond K, Dieye Y, Grifﬁths UK, Fleming J, Ba O, Diallo N, et al. Prospective
cohort study of disabling sequelae and quality of life in children with bacterial
meningitis in urban Senegal. Pediatr Infect Dis J 2010;29:1023–9.
8. Saha SK, Khan NZ, Ahmed A, Amin MR, Hanif M, Mahbub M, et al. Neurode-
velopmental sequelae in pneumococcal meningitis cases in Bangladesh: a
comprehensive follow up study. Clin Infect Dis 2009;48(Suppl 2):S90–6.
9. Logan SA, MacMahon E. Viral meningitis. BMJ 2008;5:36–40.
10. Lee BE, Davies HD. Aseptic meningitis. Curr Opin Infect Dis 2007;20:272–7.
11. Annual Report 2009. Suva: Ministry of Health Fiji, Government Printing; 2009.
12. Kong F, Brown M, Sabananthan A, Zeng X, Gilbert GL. Multiplex PCR-based
reverse line blot hybridization assay to identify 23 Streptococcus pneumoniae
polysaccharide vaccine serotypes. J Clin Microbiol 2006;44:1887–91.
13. Zhou F, Kong F, Tong Z, Gilbert GL. Identiﬁcation of less-common Streptococcus
pneumoniae serotypes by a multiplex PCR-based reverse line blot hybridization
assay. J Clin Microbiol 2007;45:3411–5.
14. Scott JA, Obiero J, Hall AJ, Marsh K. Validation of immunoglobulin G enzyme-
linked immunosorbent assay for antibodies to pneumococcal surface adhesin A
in the diagnosis of pneumococcal pneumonia among adults in Kenya. J Infect Dis
2002;186:220–6.
15. Siafakas N, Georgopoulou A, Markoulatos P, Spyrou N, Stanway G. Molecular
detection and identiﬁcation of an enterovirus during an outbreak of aseptic
meningitis. J Clin Lab Anal 2001;15:87–95.
16. Colquhoun SM, Russell FM, Carapetis JR, Tikoduadua LV, Prior J, Wake M, et al. A
cohort study to assess quality of life in young Fijian children who have a history
of bacterial meningitis. PO2.13:14518. Proceedings of the 5th International
Symposium on Pneumococci and Pneumococcal Diseases Program, Alice
Springs, Australia, 2006.
17. Varni JW, Seid M, Rode CA. The PedsQLTM: measurement model for the Pediatric
Quality of Life Inventory. Med Care 1999;37:126–39.
18. Varni JW, Seid M, Kurtin PS. Reliability and validity of the Pediatric Quality of
Life InventoryTM version 4.0 Generic core scales in healthy and patient popula-
tions. Med Care 2001;39:800–12.
19. Kempsell KE, Cox CJ, Hurle M, Wong M, Wilkie S, Zanders ED, et al. Detection of
Mycobacterium tuberculosis group organisms in human and mouse joint tissue
by reverse transcriptase PCR: prevalence in disease synovial tissue suggests
lack of speciﬁc association with rheumatoid arthritis. Infect Immun 2000;68:
6012–26.
20. Ra˚dstro¨m P, Ba¨ckman A, Qian N, Kragsbjerg P, Pa˚hlson C, Olce´n P. Detection of
bacterial DNA in cerebrospinal ﬂuid by an assay for simultaneous detection of
Neisseria meningitidis, Haemophilus inﬂuenzae, and streptococci using a semi-
nested PCR strategy. J Clin Microbiol 1994;32:2738–44.
21. Lane DJ. 16S/23S rRNA sequencing. In: Stackebrandt E, Goodfellow M, editors.
Nucleic acid techniques in bacterial systematics. Chichester, UK: Wiley & Sons;
1991. p. 115–75.
22. Kempsell KE, Cox CJ, McColm AA, Bagshaw JA, Reece R, Veale DJ, et al. Detection
of Mycobacterium tuberculosis group organisms in human and mouse joint
tissue by reverse transcriptase PCR: prevalence in diseased synovial tissue
suggests lack of speciﬁc association with rheumatoid arthritis. Infect Immun
2001;69:1821–31.
23. Perevoscikovs J, Luckenco I, Nikiforova R. Outbreak of enteroviral meningitis in
Latvia, August–October 2006. Euro Surveill 2006;11. E061005.2.
24. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus inﬂuenzae
serotype b (Hib) disease following implementation of a booster campaign. Arch
Dis Child 2008;93:665–9.
25. Levine OS, Cherian T, Hajjeh R, Knoll MD. Progress and future challenges in
coordinated surveillance and detection of pneumococcal and Hib disease in
developing countries. Clin Infect Dis 2009;48(Suppl 2):S33–6.
26. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in
infancy in England and Wales: follow up at age 5 years. BMJ 2001;323:1–5.
27. Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. Invasive pneumo-
coccal disease in central Australia. Med J Aust 1995;162:182–6.
28. Stanley U, Adegbola R, Mulholland K, Shabbar J, Stephen H, Anslem O, et al.
Epidemiology of invasive pneumococcal disease in the Western Region, The
Gambia. Pediatr Infect Dis J 1998;17:23–8.
29. Roche PW, Krause VL, Bartlett M, Coleman D, Cook H, Davis C, et al. Invasive
pneumococcal disease in Australia, 2004. Commun Dis Intell 2006;30:80–92.
30. Molyneux E, Walsh A, Amos P, Molyneux M. Acute bacterial meningitis in
children admitted to the Queen Elizabeth Central Hospital, Blantyre, Malawi in
1996–97. Trop Med Int Health 1998;3:610–8.
31. Russell FM, Carapetis JR, Ketaiwai S, Kunabuli V, Taoi M, Tikoduadua L, et al.
Pneumococcal nasopharyngeal carriage and patterns of penicillin resistance in
young children in Fiji. Ann Trop Pediatr 2006;26:187–97.
32. Magree HC, Russell FM, Sa’Aga R, Greenwood P, Tikoduadua L, Pryor J, et al.
Chest X-ray-conﬁrmed pneumonia in children in Fiji. Bull World Health Organ
2005;83:427–33.
33. Russell FM, Carapetis JR, Tikoduadua L, Chandra R, Seduadua A, Satzke C, et al.
Invasive pneumococcal disease in Fiji: clinical syndromes, epidemiology, and
the potential impact of pneumococcal conjugate vaccine. Pediatr Infect Dis J
2010;29:870–2.
34. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al.
Epidemiology of invasive Streptococcus pneumoniae infections in the United
States, 1995–1998: opportunities for prevention in the conjugate vaccine era.
JAMA 2001;285:1729–35.
35. Martin DR, Walker JS, Lennon DR. New Zealand epidemic of meningococcal disease
identiﬁed by a strain with phenotype B:4:P1.4. J Infect Dis 1998;177:497–500.
36. Franco-Paredes C, Lammoglia L, Hernandez I, Santos-Preciado J. Epidemiology
and outcomes of bacterial meningitis in Mexican children: 10-year experience
(1993–2003). Int J Infect Dis 2008;12:380–6.
37. Kornelisse RF, Westerbeek CM, Spoor AB, van der Heijde R, Spanjaard L, Neijens
HJ, et al. Pneumococcal meningitis in children: prognostic indicators and
outcomes. Clin Infect Dis 1995;21:1390–7.
38. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moı¨si JC, Were F, Levine OS. Sequelae
due to bacterial meningitis among African children: a systematic literature
review. BMC Med 2009;7:47.
39. Cortese MM, Wolff M, Almeido-Hill J, Reid R, Ketcham J, Santosham M. High
incidence rates of invasive pneumococcal disease in the White Mountain
Apache population. Arch Intern Med 1992;152:2277–82.
40. Sheridan GE, Masters CI, Shallcross JA. Detection of mRNA by reverse transcrip-
tion-PCR as an indicator of viability in Escherichia coli cells. Appl Environ
Microbiol 1998;64:1313–8.
41. Moisi JC, Saha SK, Falade AG, Njanpop-Lafourcade B, Oundo J, Zaidi A, et al.
Enhanced diagnosis of pneumococcal meningitis with use of Binax NOW
immunochromatographic test of Streptococcus pneumoniae antigen: a multisite
study. Clin Infect Dis 2009;48(Suppl 2):S49–56.
V.L. Biaukula et al. / International Journal of Infectious Diseases 16 (2012) e289–e295 e295
